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Abstract
Background: Atypical femoral fractures (AFFs) are rare events associated with increased duration of bisphosphonate
exposure. Recommended management of AFFs include cessation of bisphosphonates and imaging of the contralateral
femur. The aims of this study were to identify the local incidence of AFFs in bisphosphonate users and to audit the
medical management of AFFs against published recommendations.
Methods: A retrospective analysis of the admissions database for a major trauma centre identified all femoral fractures
(3150) in a five-year period (July 2009 to June 2014). Electronic health records and radiographs were reviewed using
the 2013 American Society for Bone and Mineral Research (ASBMR) diagnostic criteria for AFF to establish the number
of cases. To estimate incidence, the total number of bisphosphonate users was derived from primary care prescription
and secondary care day-case records. Medical management of cases with AFF on bisphosphonates was audited
against guidance from ASBMR and Medicines & Healthcare Products Regulatory Agency.
Results: 10 out of 3150 femoral fractures met criteria for AFF; 7 of these patients had a history of exposure to
bisphosphonates (6 oral, 1 intravenous). There were 19.1 AFFs per 100,000 years of bisphosphonate use in our
region. Bisphosphonates were stopped and the contralateral femur imaged in only 2 of the 7 patients treated
with bisphosphonates.
Conclusion: Our local incidence is in line with published figures; however, this is the first published evidence
suggesting that medical management and identification of AFF may be suboptimal. Managing these patients
remains challenging due to their rarity and possible lack of awareness.
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Background
Atypical femoral fractures (AFFs) are rare injuries that
have received increasing attention in the scientific litera-
ture in recent years. There is growing evidence that bis-
phosphonate exposure contributes to the risk of these
fractures. AFFs have also been reported after treatment
with other, non-bisphosphonate, antiresorptives such as
Denosumab [1]. In 2013, the American Society for Bone
and Mineral Research (ASBMR) task force published
their second report on AFFs in which the case definition
was refined in light of new evidence [2]. In summary,
the case defining criteria may be divided into clinical,
anatomical, and radiographic categories. These fractures
occur through low energy mechanisms. They are located
between the lesser trochanter and the supracondylar
flare. They are non- or minimally comminuted and ori-
ginate from the lateral cortex with evidence of cortical
flaring or beaking. Specific exclusions include neck of
femur, periprosthetic, and pathological fractures.
Subsequent to the publication of the first report of the
ASBMR taskforce, and the adoption of the 2010 case-
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defining criteria [3], several studies attempted to investi-
gate the epidemiology of AFFs in the USA, Switzerland,
and Sweden. The heterogeneous methodology employed
has made comparisons challenging. However, studies
using radiographic adjudication against ASBMR criteria
indicate the incidence of AFF varies from 1.8 to 113 per
100,000 patient years of exposure to bisphosphonates
[4–7]. A more recent study, using the 2013 ASBMR
criteria, identified an incidence of 110 per 100,000 pa-
tient years of exposure [8].
The relationship between bisphosphonate exposure
and AFF is thought to be due to the inhibition of osteo-
clastic activity with a coupled inhibition of osteoblasts
leading to failure of repair of microfractures [4, 8, 9].
Unlike osteonecrosis of the jaw (ONJ), which is most
commonly seen in patients on high-dose bisphospho-
nates for malignancy [10], AFFs are most likely to occur
in patients on standard-dose treatment, although a dose-
response relationship has been identified [9]. Further,
while they were first described in a small group of pa-
tients treated with alendronate [11], the contribution of
bisphosphonates seems to be a class effect rather than
specific to a single drug [2]. Concern about atypical frac-
tures underpins the increasing move to promote bis-
phosphonate drug holidays; however, it is estimated that
for every AFF that develops, 36 insufficiency fractures
are prevented [12].
Both the ASBMR [2, 3] and MHRA [13] provide guid-
ance on the medical management of AFFs which in-
cludes: cessation of antiresorptive; consideration of
teriparatide in cases of poor fracture healing; ensuring
the patient is replete in calcium and vitamin D, and en-
suring the contralateral femur is imaged. In the absence
of randomised controlled trials, this is based on expert
opinion and anecdotal case reports. In terms of opera-
tive treatment, the 2013 ASBMR report recommends
the use of intramedullary nailing and the avoidance of
locking plates.
The aims of this study were to identify the number of
cases of AFF in our centre, calculate incidence of AFF in
bisphosphonate users, and to audit the medical manage-
ment of AFF.
Methods
A retrospective review of an electronic trauma admissions
database at a major trauma centre was performed.
Records were retrieved for a 5-year period from 01/07/
2009 to 30/06/2014. Initially, all femoral fractures were
identified; subsequently, information in the database
allowed the exclusion of neck of femur fractures, high-
energy injuries, pathological fractures, and peri-prosthetic
fractures. The definition of pathological fractures used in
this study is taken from the ASBMR report: “fractures as-
sociated with primary or metastatic bone tumors and
miscellaneous bone diseases (e.g. Paget’s disease, fibrous
dysplasia).”
The radiographs of all of the remaining femoral frac-
tures were reviewed by one author (NE) to determine
whether they met the radiological and anatomical inclu-
sion criteria: location from the lesser trochanter to the
flair of the femoral condyle, origination at the lateral
cortex, cortical beaking, periosteal thickening, and sub-
stantially horizontal fracture orientation. A random sam-
ple of 50 out of those selected for radiograph review
were reviewed independently by both ZP and NE in
order to establish inter-rater agreement against inclusion
criteria. At the time of radiographic adjudication the
authors were blinded to the exposure of the patients to
antiresorptive treatment. Electronic health records of the
confirmed atypical femoral fracture group were reviewed
to determine demographic information, bisphosphonate
exposure, calcium and vitamin D use, glucocorticoid and
proton pump inhibitor use and management.
To determine the number of patient years of bisphospho-
nate treatment over the audit period, the total number of
oral bisphosphonate prescriptions issued in primary care
over the audit period was identified from data analysts in
two local Clinical Commissioning Groups that cover the
catchment area of the acute trust. The footprint of these
CCGs maps directly to the catchment of the acute trust
and all patients with femur fractures in these catchment
areas would automatically be referred to this trauma centre
for fracture repair, and not elsewhere. In addition, data on
the number of intravenous bisphosphonate users over the
same period was estimated based on the number receiving
treatment in 2015. These figures were combined to calcu-
late the total number of patient years of BP exposure over
the 5 year period.
Medical management of bisphosphonate-associated
AFF patients was audited against the following standards:
 cessation of bisphosphonate treatment [2]
 assessment of calcium and vitamin D status with
supplementation if required [2]
 radiographic examination of the contralateral femur
[13]
Assessment of calcium and vitamin D status was eval-
uated by looking for comments on calcium intake or
vitamin D status in the electronic health records, pre-
scription of calcium and vitamin D or serum measure-
ment of vitamin D. As the primary aim of the study was
to audit medical management, ethical approval was not
deemed necessary.
Results
Figure 1 demonstrates the process used to identify the
definitive cases of atypical femoral fracture. Of 3150
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femoral fractures, 112 were selected for radiograph
review. 10 fractures were confirmed AFF over the 5 year
period, representing 0.32% (10/3150) of all femoral
fractures (including neck of femur fractures) and 8.9%
(10/112) of all low energy femoral shaft and subtrochan-
teric fractures. There was complete agreement between
the two adjudicators for radiographic diagnosis of
AFF against ASBMR 2013 criteria (Cohen’s Kappa
statistic of 1).
Seven of the 10 patients with confirmed AFF had pre-
viously been exposed to bisphosphonates: 6 oral alendro-
nic acid and 1 intravenous Pamidronate. One additional
patient who met the radiographic criteria had pre-
fracture exposure to Denosumab but also had chronic
kidney disease stage 5 and was therefore excluded due
to the high possibility of renal metabolic bone disease.
One patient, not on bisphosphonates, was treated with
oral glucocorticoids. Three bisphosphonate treated
patients were also treated with proton pump inhibitors.
No patients had a diagnosis of rheumatoid arthritis.
The mean age of the AFF cohort was 72.8 years
(range: 57 to 88) and all but one of the patients were
female. The duration of bisphosphonate use ranged
from 3–15 years (it was not possible to obtain these
data for 2 patients). See Table 1 for the demographic
data for each patient.
Primary care records identified 34,157 patient-years of
oral bisphosphonate treatment prescribed in the region
during the study period. Additionally, 2485 patient-years
of exposure to intravenous bisphosphonates were esti-
mated from secondary care day-case records. 7 AFFs oc-
curred in 36642 patient years of treatment equating to
an estimated incidence of 19.1 per 100,000 patient years
of bisphosphonate exposure. In terms of operative man-
agement, 8 patients with AFF were treated with intrame-
dullary nailing (of which one patient also received
prophylactic nailing of the contralateral femur), 1 was
treated with a dynamic hip screw and 1 was treated with
a proximal locking plate.
Medical and operative management is summarised in
Table 1. Of the 7 patients with pre-fracture exposure to
bisphosphonates, 2 had bisphosphonates discontinued.
In these two patients, the treating orthopaedic surgeon
had diagnosed AFF. A diagnosis of AFF was not made in
the other 5 cases by the treating orthopaedic surgeon.
Eight of the 10 radiographs were reported and none of
the radiologists’ reports mentioned AFF. Imaging of the
contralateral femur was performed in 2 of the 7 con-
firmed AFF cases on bisphosphonates. One of these had
increased cortical thickening on the contralateral side
and proceeded to have prophylactic nailing. No patients
had bilateral AFF at the time of the index event although
one patient had a midshaft fracture on the contralateral
side 3 years prior to the AFF identified in this study
(pre-fixation radiographs of the contralateral fracture
not available).
Out of the 10 confirmed AFF patients, 3 patients were
discharged on calcium/vitamin D supplements. In the
other 7 patients, there was no mention in the electronic
health record of assessment of calcium and vitamin D
status and serum vitamin D was not checked at the time
of fracture. Orthopaedic follow up was insufficiently long
to judge healing in 5 of the 7 bisphosphonate related
AFF, however no patient represented with symptomatic
delayed or non-union to date. Of the 2 patients with for-
mal follow up of more than 9 months no concerns were
recorded relating to fracture healing. Subsequent to this
study, all patients’ general practitioners were contacted
to inform them of the diagnosis of AFF, suggest any BP
be discontinued and invite the patients for review in a
secondary care bone clinic to review osteoporosis
management.
Fig. 1 Flow chart demonstrating case identification process. This
flowchart outlines the steps taken to identify cases of AFF as
defined by the 2013 ASBMR Report. Clinical and radiological
inclusion and exclusion criteria are described in greater detail in
the methods section
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Discussion
This study has demonstrated that, using the updated
ASBMR 2013 criteria, there were 10 AFFs diagnosed at
our Major Trauma Centre in the 5 years from July 2009
to June 2014. Of these, 7 were associated with bisphos-
phonate use. This is the first study to estimate the inci-
dence of AFF in the UK using the updated ASBMR
criteria. The local estimated incidence of 19.1 AFFs per
100,000 years of bisphosphonate treatment is similar to
previous radiographically adjudicated studies using
either the 2010 or 2013 ASBMR case definitions of AFF
[5, 7]. However the estimated incidence in this study
and others is markedly lower than that found by investi-
gators in Sweden who report rates of 5–11 per
10,000 years of bisphosphonate use [4, 8].
In addition, this is the first published audit of the med-
ical management of these rare events. Our results show
that several patients did not receive optimal post-AFF
medical management as described in the guidance pub-
lished by the MHRA and ASBMR. One possible explan-
ation for this finding is that these fractures were
diagnosed correctly but there was a subsequent lack of
awareness of recommended management guidelines.
However, it is the conjecture of the authors that some of
these injuries were not recognised for what they were at
the time of hospitalisation by orthopaedic surgeons or
radiologists. This is the first study to our knowledge that
has reported on whether or not AFF was diagnosed at
the time of event by orthopaedic surgeon; however a
previously published Canadian audit demonstrated that
AFFs were not recognised by radiologists in all but one
of 24 cases [14].
The reason for this is likely to be the infrequency of
clinicians’ exposure to AFFs. While the exact number
varies over time, our Major Trauma Centre has approxi-
mately 12 consultants admitting trauma. This means
that, on average, each consultant might be expected to
admit an AFF only once every 6 years (or only every
8.6 years for an AFF in a patient exposed to
bisphosphonates).
The calculation of incidence is subject to three import-
ant limitations. First, our estimate of the number of
years of oral bisphosphonate exposure is calculated using
prescription data. Adherence to bisphosphonate treat-
ment is poor with as many as half of patients discontinu-
ing at one year [15]. As a result, the number of years of
actual bisphosphonate exposure may be inflated and the
incidence underestimated. Additionally, an approxima-
tion of the number of patient-years of intravenous
bisphosphonate therapy was made due to limitations of
secondary care prescribing records. As there are propor-
tionately far fewer patients on injectable bisphosphonates
Table 1 Atypical Femoral Fracture cases demographics and medical management
Sex Age Radiographic
features of AFFa
Antiresorptive
treatment pre-fracture
Cessation of BP
post fractureb
Contralateral imaging
performed
Assessment of Calcium
and Vitamin D statusc
Operative Managementd
F 66 All major criteria
1 minor
None N/A No No Proximal femoral locking plate
M 77 All major criteria
1 minor
Alendronic Acid No No No IM Nail
F 88 All major criteriae
1 minor
None N/A No No DHS
F 80 All major criteria
1 minor
None N/A No No IM Nail
F 63 All major criteriaf Alendronic Acid No Nof No IM Nail
F 69 All major criteria
1 minor
Alendronic Acid Yes Yes No Bilateral IM Nail
F 77 All major criteria
1 minor
Pamidronate No No on supplements IM Nail
F 70 All major criteria
1 minor
Alendronic Acid No No on supplements IM Nail
F 85 All major criteria
1 minor
Alendronic Acid Yes Yes on supplements IM Nail
F 57 All major criteria
1 minor
Alendronic Acid No No No IM Nail
a It was not possible to determine the minor features relating to prior symptoms, or to determine bilaterality when contralateral imaging was not performed.
When a minor feature was present, this related to increased cortical thickening. Poor healing was not mentioned in any electronic health records
b N/A not applicable
c Determined by mention of calcium and vitamin D status in the electronic health record, check of serum vitamin D or whether patient was on supplements
d IM intramedullary nail; DHS dynamic hip screw
e This fracture was incomplete
f This patient had sustained a midshaft fracture on the contralateral side 3 years previously
Eisenstein et al. BMC Musculoskeletal Disorders  (2017) 18:29 Page 4 of 6
than oral treatment, (6.8% of the total) we do not believe
this estimation will have had a marked effect on our re-
sults. Finally, we have made an assumption that the
catchment of the CCGs matched the acute Trust catch-
ment. In 2012, the Trust was awarded major trauma status
to act as a tertiary centre for the wider population of 2.25
million in the North West Midlands and North Wales; as
AFFs are not a product of major trauma, we considered
this not to have adversely affected our results. The ad-
dresses of all the bisphosphonate treated AFF cases were
confirmed as belonging to our CCG catchment areas. It is
possible the hospital treated patients with fracture from
neighbouring CCGs, which would result in an overesti-
mate of incidence.
This study has three important messages for clinical
practice. First, we have identified that patients with AFF
are at risk of being managed without reference to the
recommendations of the ASBMR or MHRA. By publish-
ing our data, we hope to raise awareness of these rare
events and their management. Previous reports suggest
between 22 and 83% of those with AFF have a bilateral
fracture or radiographic abnormality and therefore
contralateral imaging is crucial. The authors acknow-
ledge, however, that the published management recom-
mendations based on drug cessation are based on
low-level evidence. This is due to the difficulty in power-
ing high quality studies that investigate such rare events.
One possible solution to both raise awareness within or-
thopaedics and to investigate association and outcomes
might be to establish a national or international registry
of these fractures.
The second important clinical message from these
findings is that despite being rare overall, these injuries
make up nearly 9% of all “low energy” femoral fractures.
Therefore, a diagnosis of “low-energy” femoral fracture
should prompt a high level of suspicion of AFF. Finally,
robust local pathways need to be developed between ad-
mitting teams and osteoporosis services so that, when
AFFs are recognised, the patients’ osteoporosis treat-
ment may be reviewed appropriately.
Conclusion
AFFs are rare and can occur both with and without
exposure to bisphosphonates. Our local incidence is
comparable to internationally reported figures. Medical
management is challenging due to the rarity of these
events. We propose that increased awareness and multi-
speciality working would serve to improve the manage-
ment of these patients.
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